Renaud B. Maloberti - 28 Mar 2022 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Role
Chief Commercial Officer
Signature
/s/ Renaud B. Maloberti by Mark Busch, attorney-in-fact
Issuer symbol
NDRA
Transactions as of
28 Mar 2022
Transactions value $
$0
Form type
4
Filing time
30 Mar 2022, 17:16:03 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NDRA Stock Options Award $0 +186K $0.00 186K 28 Mar 2022 Common Stock 186K $0.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.